Concepedia

Mark Burgert

MB

Statistics

Publications

9

Citations

1K

H-Index

9

Active since

2005

Affiliations

GlaxoSmithKline (United States)(Current)

GlaxoSmithKline (United Kingdom)

Hospital of the University of Pennsylvania

Pathways Behavioral Services

University of Pennsylvania

Mark Burgert is an author at GlaxoSmithKline (United States) specializing in medicine, pharmacology, and cardiology.

Publications per year

2005–2019

9

Publications

9

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

Robert L. Wilensky, Yi Shi, Emile R. Mohler et al. · Nature Medicine · 2008 · 388 citations · Full text

, , +14

An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure

Kevin S. Thorneloe, Mui Cheung, Weike Bao et al. · Science Translational Medicine · 2012 · 336 citations

, , +10

Synthetic LXR agonists increase LDL in CETP species

Pieter H.E. Groot, John Yates, Claire J. Stocker et al. · Journal of Lipid Research · 2005 · 119 citations · Full text

, , +16

Tumor-Specific Efficacy of Transforming Growth Factor-βRI Inhibition in Eker Rats

Nicholas J. Laping, Jeffrey I. Everitt, Kendall S. Frazier et al. · Clinical Cancer Research · 2007 · 67 citations

, , +16

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease

William C. Reisdorf, Qing Xie, Xin Zeng et al. · PLoS ONE · 2019 · 35 citations · Full text

, , +17

1–5 of 9